RxDoctor Payments Data

Paramvir Singh, MD

Gastroenterology · Redding, CANPI 1346213444

Payments from drug & device makers

$8,110in general payments, 2019–2025

Across 120 payments — averaging $67.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • AbbVie$742
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$399
  • Takeda Pharmaceuticals U.S.A., Inc.$268
  • Madrigal Pharmaceuticals$216
  • Intercept Pharmaceuticals, Inc.$118
  • plus $333 from 9 others

What the payments were for

  • Speaking & faculty fees$4,92061%
  • Travel & lodging$97712%
  • Food & beverage$2,21227%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,110 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$117,126
Medicare patients
493
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase26$97,712
CreonLipase/Protease/Amylase33$84,774
XifaxanRifaximin15$45,615
Mesalamine20$3,770
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg148$3,251
Budesonide EcBudesonide15$2,868
CholestyramineCholestyramine (With Sugar)34$2,391
Omeprazole178$2,147
Azathioprine15$1,878
Esomeprazole Magnesium19$1,314
Pantoprazole Sodium56$773
Dicyclomine Hcl29$720
Colesevelam Hcl12$660
Gabapentin22$577
Metoclopramide Hcl39$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$19$97,71226 claims
AbbVieCreon$742$84,77433 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$399$45,61515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →